Deferasirox: The new oral iron chelator

Indian Pediatrics

Volumn 44, Issue 8, 2007, Pages 603-607

  Dubey, A P ^a   Sudha, S ^a   Parakh, Ankit ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Deferasirox; Iron chelator; Thalassemia

Indexed keywords

CHELATING AGENT; DEFERASIROX; DEFERIPONE; DEFEROXAMINE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; AGRANULOCYTOSIS; ARTHROPATHY; BONE DISEASE; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; EYE TOXICITY; FEVER; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEADACHE; HUMAN; IRON CHELATION; NAUSEA; OTOTOXICITY; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; THALASSEMIA; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VOMITING;

BENZOIC ACIDS; CHILD; CHILD, PRESCHOOL; HUMANS; IRON CHELATING AGENTS; THALASSEMIA; TRIAZOLES;

EID: 34548304042     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci 2005; 1054: 445-450.
2. Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassemia. Cochrane Database Syst Rev. 2005; 19: CD004450.
3. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine - or deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733-3737.
4. Oral drug for iron overload. FDA Consum 2006; 40: 5.
5. Nick H, Acklin P, Lattmann R, Buehlmayer P, Hauffe S, Schupp J, Alberti D. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chern 2003; 10: 1065-1076.
6. Galanello R, Piga A, Alberti O, Rouan MC, Bigler H, Sechaud R, et al. Safety, tolerability and pharmacokinetics of ICL 670, a new orally active ironchelating agent in patients with transfusion-dependent ironoverload due to beta thalassemia. J Clin Pharmacol 2003; 43: 565-572.
7. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361: 1597-1602.
8. Porter J, Vichinsky E, Rose C, Piga A, Olivieri N, Gattermann N, et al. A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload. Blood 2004; 104: 872A.
9. Vichinsky E, Fischer R, Fung E, Onyekwere O, Porter J, Swerdlow P, et a1. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade® ICL670) is well tolerated and reduces iron. Blood 2005; 106: 95A.
10. Piga A, Galanello R, Cappellini MO, Forni GL, Lupo G, Ford JM, et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmaco kinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood 2003; 102: 121A.
11. Piga A, Galanello R, Foschini ML, Zappu A, Bordone E, Longo F, et al. Once-daily treatment with the oral iron chelator ICL670 (Exjade ®): Results of a phase II study in pediatric patients with beta thalassemia major. Blood 2004; 104: 983A.
12. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with {beta}- thalassemia. Blood 2006; 107: 3455-3462.
13. Porter J, Borgna-Pignatti C, Baccarani M, Saviano A, Abish S, Malizia R, et al. Iron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis. Blood 2005; 106: 755A.
14. Cabantchik ZI, Link G, Glickstein H, Ben R, Hershko C, Konijn AM, Nick H. Deferasirox (Exjade®, ICL670): A Journey into Labile Iron Centers of Living Cardiomyocytes. Blood 2005; 106: 824A.
15. Wood JC, Duessel MO, Gonzales I, Aguilar M, Nick H, Shimada H, et al. ICL670 Removes Cardiac Iron in a Gerbil Model of Iron Overload. Blood 2005; 106: 2695A.
16. Porter JB, Tanner MA, Pennell DJ, Eleftheriou P. Improved myocardial T2* in transfusion dependent anemias receiving ICL670 (deferasirox). Blood 2005; 106: 1003A.
17. Porter J, Waldmeier F, Bruin G, Shah F, Hazell K, Warrington S, et al. Pharmacokinetics, metabolism and elimination of the iron chelator drug ICL670 in beta-thalassemia patient. Blood 2002; 11: 3720A.
18. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001; 138: 130-138.